Artelo has expanded into ophthalmology by launching a fully funded investigator-sponsored clinical study of ART27.13 in glaucoma patients, with first patient enrollment expected in Q2 2026. The study is backed by Glaucoma UK and the HSC R&D Division and will be led by Augusto Azuara-Blanco at Queen’s University Belfast. ART27.13 is an oral, peripherally selective synthetic cannabinoid receptor agonist being evaluated for its effects on intraocular pressure. The document cites the global glaucoma market at USD 9.46 billion in 2025, projected to reach USD 16.31 billion by 2033.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180807PRIMZONEFULLFEED9674237) on March 18, 2026, and is solely responsible for the information contained therein.